scholarly journals Inhibition of MicroRNA-381 Promotes Tumor Cell Growth and Chemoresistance in Clear-Cell Renal Cell Carcinoma

2019 ◽  
Vol 25 ◽  
pp. 5181-5190 ◽  
Author(s):  
Yunhui Chan ◽  
Yipeng Yu ◽  
Gang Wang ◽  
Changlin Wang ◽  
Daming Zhang ◽  
...  
2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Maxime Benoit ◽  
Edouard Fortier ◽  
Magalie Barth ◽  
Vincent Procaccio ◽  
Jennifer Bourreau ◽  
...  

2018 ◽  
Vol 17 (2) ◽  
pp. e57-e59
Author(s):  
M. Benoit ◽  
E. Fortier ◽  
M. Barth ◽  
V. Procaccio ◽  
J. Bourreau ◽  
...  

2008 ◽  
Vol 14 (16) ◽  
pp. 5150-5157 ◽  
Author(s):  
Paul L. Crispen ◽  
Yuri Sheinin ◽  
Timothy J. Roth ◽  
Christine M. Lohse ◽  
Susan M. Kuntz ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (5) ◽  
pp. e0129404 ◽  
Author(s):  
Feng-qiang Yang ◽  
Hai-min Zhang ◽  
Shao-Jun Chen ◽  
Yang Yan ◽  
Jun-hua Zheng

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chunxiu Yang ◽  
Jingjing Pang ◽  
Jian Xu ◽  
He Pan ◽  
Yueying Li ◽  
...  

Abstract Background Clear cell renal cell carcinoma (ccRCC), derived from renal tubular epithelial cells, is the most common malignant tumor of the kidney. The study of key genes related to the pathogenesis of ccRCC has become important for gene target therapy. Methods Bioinformatics analysis of The Cancer Genome Atlas (TCGA), the NCBI Gene Expression Omnibus (GEO) database, USUC Xena database, cBioPortal for Cancer Genomics, and MethSurv were performed to examine the aberrant genetic pattern and prognostic significance of leucine-rich repeat kinase 2 (LRRK2) expression and its relationship to clinical parameters. Immunohistochemistry and Western blot were performed to verify LRRK2 expression. The regulation of ccRCC tumor cell lines proliferation by LRRK2 was examined by CCK8 assay. Results Bioinformatics analysis showed that LRRK2 expression was up-regulated and largely correlated with DNA methylation in ccRCC. The up-regulation of LRRK2 was confirmed in ccRCC tissue immunohistochemically and by protein analysis. The level of expression was related to gender, pathological grade, stage, and metastatic status of ccRCC patients. Meanwhile, Kaplan–Meier analysis showed that high expression of LRRK2 correlates to a better prognosis; knockdown of LRRK2 expression attenuated the proliferation ability of ccRCC tumor cell lines; protein–protein interaction network analysis showed that LRRK2 interacts with HIF1A and EGFR. Conclusion We found that LRRK2 may play an important role in the tumorigenesis and progression of ccRCC. Our findings provided a potential predictor and therapeutic target in ccRCC.


2021 ◽  
Vol 11 ◽  
Author(s):  
Tuo Deng ◽  
Zihao He ◽  
Xiaolu Duan ◽  
Di Gu ◽  
Chao Cai ◽  
...  

Background: Signal transducing adaptor molecule 1 (STAM1) was considered to mediate cell growth and be involved in multiple signaling pathways; however, no research on the role of STAM1 in any tumors has been published yet. Our study aimed to investigate the prognostic value of STAM1 for clear cell renal cell carcinoma (ccRCC) and its role in modulating cancer cell function.Methods: Data from The Cancer Genome Atlas (TCGA) in December 2019 were used to examine the role of STAM1 in indicating ccRCC patients' survival. A purchased tissue microarray (TM) and fresh ccRCC renal tissues were used for further validation. Then, STAM1 was overexpressed in human ccRCC cell lines for in vitro assays. Finally, bioinformatics was performed for STAM1 protein–protein interaction (PPI) network construction and functional analyses.Results: A total of 539 ccRCC and 72 control samples were included for the TCGA cohort, and 149 ccRCC and 29 control slices were included for the TM cohort. In the TCGA and TM cohorts, we found that STAM1 expression was lower in ccRCC compared with normal adjacent non-cancerous renal tissues (P < 0.0001 for both cohorts). STAM1 downregulation was also related to significantly shorter overall survival (OS) (P < 0.0001 for both cohorts). In the TCGA cohort, reduced STAM1 expression was also associated with aggressive features of the tumor. Under multivariate analyses, STAM1 was demonstrated to be an independent prognostic factor for ccRCC survival in both TCGA (HR = 0.52, 95% CI: 0.33–0.84, P = 0.007) and TM cohorts (HR = 0.12, 95% CI: 0.04–0.32, P < 0.001). Our in vitro experiments showed that STAM1 inhibited cell viability, invasion, and migration in ccRCC cell lines. In PPI network, 10 candidate genes categorized into five biological processes were found to be closely related to STAM1.Conclusion: STAM1 is a promising prognostic biomarker for predicting ccRCC survival outcomes. Preliminary pathogenesis is demonstrated by our in vitro experiments. Further pathological mechanisms of STAM1 in modulating ccRCC require comprehensive laboratory and clinical studies.


Sign in / Sign up

Export Citation Format

Share Document